Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Biologics

Syda Productions/shutterstock.com

Tips, Resources to Help Rheumatologists Educate Patients on Biologics and Biosimilars

Vanessa Caceres  |  February 15, 2017

Rheumatologists are accustomed to educating patients about medications—but biologic medications require some additional time and discussion. “Biologics are inherently more complex [than other medications], and there are multiple issues to consider before initiating treatment,” says K. “Kwas” Huston, MD, The Center for Rheumatic Disease, Kansas City, Mo. “This includes the patient’s disease activity, prior medications…

Filed under:Biologics/DMARDsDrug UpdatesPractice Support Tagged with:Association of Rheumatology Professionals (ARP)BiologicsDrugspatient carePractice ManagementQualityrheumatologistrheumatologySafetytherapyTreatment

Do RA Patients in Clinical Trials for Biologics Represent the Average?

Arthritis Care & Research  |  October 4, 2016

It’s estimated that a majority of patients with rheumatoid arthritis (RA) have been exposed to biologic treatments. However, the randomized controlled trials demonstrating the safety and efficacy of these biologic agents have strict participant eligibility requirements. New research has examined the requirements of 30 trials for biologics and applied those standards to two large clinical cohorts. The result: A majority of these RA patients did not satisfy the criteria…

Filed under:Biologics/DMARDs Tagged with:BiologicsBiologics & Biosimilarsclinical trialsnon-TNF biologicsrandomized controlled trialTNF inhibitors

New Research into Rheumatoid Arthritis, Gout Includes Updates on Methotrexate, Biologics, Ultrasound

Thomas R. Collins  |  September 8, 2016

LONDON—From optimizing responses to methotrexate, to the efficacy of biologics, to the need for imaging in assessing remission, the literature, as ever, has been lively with explorations of pressing topics in the treatment and management of rheumatoid arthritis. Josef Smolen, MD, chair of rheumatology at the Medical University of Vienna, reviewed many of the highlights…

Filed under:ConditionsDrug UpdatesGout and Crystalline ArthritisResearch RheumRheumatoid Arthritis Tagged with:Biologicsdrug updateEULAREuropean League Against RheumatismGoutMethotrexatepatient careResearchRheumatoid arthritisrheumatologistTreatmentUltrasound

Arthritis Patients Lack Knowledge about Safe Use of Biologics

Will Boggs, MD  |  June 15, 2016

NEW YORK (Reuters Health)—Many patients with arthritis lack the knowledge to use their biologic treatments safely, researchers from France report. “Some patients are at risk of poorly managing their biologic therapy, especially patients living alone, in a large city, patients with low education level, or (patients who are) unemployed,” Dr. Anne-Christine Rat from CHU de…

Filed under:Biologics/DMARDsDrug Updates Tagged with:ArthritisBiologicspatient education

Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk

Laura Newman  |  February 2, 2016

NEW YORK (Reuters Health)—The newer disease-modifying drugs for rheumatoid arthritis appear to offer the same or even better cardiovascular (CV) protection than older tumor necrosis factor (TNF) inhibitors, hints a large study. “We really haven’t had a good understanding on where the non-TNF biologics and CV risk stand,” Dr. Jeffrey R. Curtis of the University…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:cardiovascularDisease-modifying antirheumatic drugs (DMARDs)Myocardial infarctionnon-TNF biologicsRheumatoid Arthritis (RA)TNFtumor necrosis factor

Tips for Educating Patients in the Age of Biologics

Monica Richey, MSN, ANP-BC, GNP, BSN  |  December 15, 2015

Patient education has always been at the core of the nursing profession. Nurses pride themselves on being great teachers and patient advocates. When self-injectable biologics were first introduced to the market, one of the main goals was to make patients independent and put them in the driver’s seat of their own care. Yet without a…

Filed under:From the CollegePatient PerspectivePractice Support Tagged with:Biologicspatient carepatient educationself-injection

EULAR 2015: RA Research Shows Imperfect Guidelines, Suggests Strategies with Biologics

Thomas R. Collins  |  August 17, 2015

ROME, Italy—Even with classification criteria that have been updated and refined over time, rheumatoid arthritis is still a diagnosis that ultimately has to be made with clinical judgment, said Ronald van Vollenhoven, MD, PhD, professor of medicine and chief of clinical therapy research in inflammatory diseases at the Karolinska University in Sweden. His remarks came…

Filed under:ConditionsEULAR/OtherMeeting ReportsResearch RheumRheumatoid Arthritis Tagged with:ClinicalDiagnosisEULARpatient carePractice ManagementResearchRheumatoid arthritis

Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability

Rob Goodier (Reuters Health)  |  May 21, 2015

The costs of some disease-modifying therapies outpace prescription drug inflation, saddling insured patients with thousands of dollars in out-of-pocket payments and delayed or denied coverage, two new studies have shown. Disease-modifying therapies for multiple sclerosis are rising in cost five to seven times faster than inflation and cost more in the United States than in…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:BiologicscostsDrugsMedicareMultiple SclerosisResearchRheumatoid arthritis

Vaccines and Biologics: What Rheumatologists Need to Know

Kurt Ullman  |  December 1, 2014

How vaccines, medications and rheumatic disease-related effects on immune system interact

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:BiologicsImmune SysteminteractionResearchRheumatic DiseaserheumatologistrheumatologyrituximabUllmanvaccines

EULAR 2014: Non-Tumor Necrosis Factor Biologics Update

Thomas R. Collins  |  August 1, 2014

Clinical trials on rheumatology drugs, including sarilumab, show promise for patients with rheumatoid arthritis also taking methotrexate

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:BiologicsCollinsEULARMethotrexateRheumatoid arthritisrheumatologistrheumatologyrituximabsarilumab

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences